Botulinum toxin from Evolus (manufactured by Daewoong) — who it suits, where it is used, and what it should cost
Quick answer
Jeuveau is a botulinum toxin from Evolus (manufactured by Daewoong) (South Korea, marketed in the US). It is a type A toxin from the same production line as Nabota, marketed as Jeuveau in the US and Europe. Results typically last 3–4 months. Reference pricing is about 7,000–12,000 บาท per 100 units in Thailand versus roughly 4,000–8,000 บาท per 100 units in Korea. The average gap is around 35–40%. Registration: Thailand — Limited / selected models; Korea — Registered.
Jeuveau is a neat case study in toxin branding: the substance comes from the same Korean plant as Nabota, yet renaming it for the US channel lifts the price. Understanding that lets buyers decide whether they are paying for the marketing name or the product itself.
Technically, it is positioned purely as an aesthetic toxin and does not carry therapeutic indications in many markets. That matters because it dictates how firm or soft the product feels, how far it spreads and which tissue plane it belongs in. Experienced injectors pick the sub-model to match the site rather than choosing on brand name alone.
Popular placement: primarily glabellar lines, with practical use on forehead and crow's feet. Good planning starts from a whole-face assessment rather than filling only the spot the patient points at, because balance comes from distributing volume sensibly, not from maximising one area.
On longevity, Jeuveau typically holds 3–4 months. It fades sooner with a fast metabolism, frequent intense exercise, smoking, highly mobile areas such as lips and perioral skin, and under-dosing relative to what the face actually needs. It lasts longer with correct plane placement, a sub-model matched to local tissue pressure, and a top-up before the effect disappears completely.
Who it suits: people wanting US-brand-equivalent results at a lower price, and purely aesthetic users.
Not suitable or best avoided: anyone needing therapeutic indications such as spasticity or migraine. This also covers pregnancy and breastfeeding, active infection at the injection site, and any known allergy to the product's components.
Thailand versus Korea: reference market pricing runs about 7,000–12,000 บาท per 100 units in Thailand and roughly 4,000–8,000 บาท per 100 units in Korea. The average gap is around 35–40%. The honest comparison includes travel cost — flights, accommodation, interpreting and time. For a single small treatment the gap rarely covers a trip; combined with several procedures in one visit, the difference starts to matter.
Thai travellers can get confused asking only in English, because Korean clinics almost always say Nabota. The clearest check is to look at the box and match the manufacturer name Daewoong, which appears on both versions.
Safety and authenticity: In Thailand the same line is more often sold as Nabota, so check that the name on the box matches what you agreed to. Before treatment, ask to see the sealed box and label, check the registration number against Thailand's FDA or Korea's MFDS, photograph the lot number and expiry, and have the doctor open the product in front of you. A price far below market is usually a sign of unregistered stock or over-dilution.
Bottom line: Jeuveau is worth it when it is matched to a real concern, injected by a doctor who reads the whole face, and understood as a temporary result that needs maintenance rather than a one-off fix. Compare prices per unit or per cc of registered product — never a promotional price against a standard one.
Last updated: 2026-09-03 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.